See more : Karma Energy Limited (KARMAENG.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Kindred Biosciences, Inc. (KIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kindred Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Daiichikosho Co., Ltd. (7458.T) Income Statement Analysis – Financial Results
- Clearday, Inc. (CLRD) Income Statement Analysis – Financial Results
- K3 Business Technology Group plc (KBT.L) Income Statement Analysis – Financial Results
- Global Gold Corporation (GBGD) Income Statement Analysis – Financial Results
- Nanavati Ventures Limited (NVENTURES.BO) Income Statement Analysis – Financial Results
Kindred Biosciences, Inc. (KIN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.kindredbio.com
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.16M | 4.26M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.63M | 587.00K | 324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.54M | 3.67M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.03% | 86.21% | 83.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.28M | 28.31M | 26.40M | 17.67M | 13.86M | 19.41M | 18.69M | 3.14M | 75.00K |
| General & Administrative | 21.98M | 37.93M | 22.08M | 11.90M | 6.84M | 6.86M | 8.54M | 1.08M | 45.00K |
| Selling & Marketing | 0.00 | 0.00 | 4.42M | 2.08M | 1.47M | 992.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.98M | 37.93M | 26.50M | 13.99M | 8.31M | 7.85M | 8.54M | 1.08M | 45.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.26M | 66.24M | 52.90M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Cost & Expenses | 57.89M | 66.82M | 53.22M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Depreciation & Amortization | 4.68M | 2.54M | 805.00K | 475.00K | 155.00K | 146.00K | 58.00K | 3.13K | 0.00 |
| EBITDA | -15.29M | -58.85M | -48.89M | -30.40M | -22.34M | -26.98M | -27.08M | -4.21M | -120.00K |
| EBITDA Ratio | -36.27% | -1,382.75% | -2,486.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.97M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Operating Income Ratio | -47.36% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -56.00 | 0.00 |
| Income Before Tax | -21.80M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Income Before Tax Ratio | -51.69% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Net Income | -23.62M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Net Income Ratio | -56.03% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| EPS Diluted | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| Weighted Avg Shares Out | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
| Weighted Avg Shares Out (Dil) | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
Assenagon Asset Management S.A. Makes New $1.16 Million Investment in Kindred Biosciences Inc (NASDAQ:KIN)
Assenagon Asset Management S.A. purchased a new position in Kindred Biosciences Inc (NASDAQ:KIN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 289,387 shares of the biopharmaceutical...
Kindred Biosciences (NASDAQ:KIN) Rating Increased to Buy at Zacks Investment Research
Kindred Biosciences (NASDAQ:KIN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $4.25 target price on the biopharmaceutical company’s stock. Zacks...
Kindred Biosciences (NASDAQ:KIN) Downgraded by Zacks Investment Research to "Hold"
Kindred Biosciences (NASDAQ:KIN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Kindred Biosciences is a development-stage biopharmaceutical company...
Kindred Biosciences Inc (NASDAQ:KIN) Expected to Post Quarterly Sales of $1.75 Million
Brokerages forecast that Kindred Biosciences Inc (NASDAQ:KIN) will report sales of $1.75 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kindred Biosciences’ earnings, with the highest sales estimate coming in at $1.80...
Analysts Expect Kindred Biosciences Inc (NASDAQ:KIN) to Announce -$0.41 Earnings Per Share
Equities research analysts predict that Kindred Biosciences Inc (NASDAQ:KIN) will post earnings per share of ($0.41) for the current quarter, Zacks reports. Two analysts have provided estimates for Kindred Biosciences’ earnings, with estimates ranging from ($0.43) to ($0.39). Kindred Biosciences...
Zacks Investment Research Upgrades Kindred Biosciences (NASDAQ:KIN) to Buy
Kindred Biosciences (NASDAQ:KIN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $4.75 target price on the biopharmaceutical company’s stock....
Zacks Investment Research Downgrades Kindred Biosciences (NASDAQ:KIN) to Hold
Kindred Biosciences (NASDAQ:KIN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving...
Kindred Biosciences (NASDAQ:KIN) Raised to Buy at Zacks Investment Research
Kindred Biosciences (NASDAQ:KIN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Zacks.com reports. The firm presently has a $4.50 price target on the biopharmaceutical company’s stock....
Citigroup Inc. Has $69,000 Holdings in Kindred Biosciences Inc (NASDAQ:KIN)
Citigroup Inc. lifted its holdings in Kindred Biosciences Inc (NASDAQ:KIN) by 84.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,159 shares of the biopharmaceutical...
Edited Transcript of KIN earnings conference call or presentation 16-Mar-20 8:30pm GMT
Q4 2019 Kindred Biosciences Inc Earnings Call
Source: https://incomestatements.info
Category: Stock Reports